Research prototype, not medical advice.

Tafamidis, which stabilises transthyretin, reduces mortality and cardiovascular hospitalisations in cardiac ATTR amyloidosis (phase 3); approved.

Confidence
Established
Level of evidence
Approved by a health authority
Observed in
Human
Mission
Map of aging (12 hallmarks)
Concepts
Loss of proteostasisTafamidisTransthyretin amyloidosis (ATTR)

What the sources say

Each row is an article. “Supports”: it backs the claim. “Contradicts”: it goes against it. “Qualifies”: it limits it (another species, a weaker effect…).

DirectionSourceWhere in the articleStatus
Supports Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
Maurer et al. · New England Journal of Medicine 2018
— Verified